Professor Sherene Loi and the International Immuno-Oncology Biomarker Working Group on tumour-infiltrating lymphocytes as breast cancer biomarkers. Two Articles cover AI and digital pathology scoring methods and a Review examines integrating TILs into radiation oncology trials and clinical practice. The Articles and Review are published in the September 2026 issue of The Lancet Oncology.

To read the publications discussed, see: 

Tumour-infiltrating lymphocytes and breast radiotherapy: perspectives from the International Immuno-Oncology Biomarker Working Group:  https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00255-X

Artificial intelligence-based tumour infiltrating lymphocyte quantification in patients with triple-negative breast cancer: an independent validation study  https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00339-6   Manual, digital, and AI tumour-infiltrating lymphocyte scoring: a secondary analysis of the APHINITY randomised trial: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00247-0

Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör The Lancet Group. Innehållet i podden är skapat av The Lancet Group och inte av, eller tillsammans med, Poddtoppen.